Dossier
Albert Bourla
Coverage of Albert Bourla in the Nexus archive.
- STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer's experimental lung cancer drug sigvotatug vedotin failed in a clinical trial, which was expected to replace the chemotherapy docetaxel. The drug was acquired through Pfizer's $43 billion purchase of Seagen in 2023.
- Pfizer CEO on leaving Europe in pursuit of the American dream: The ‘opportunities are enormous’
Pfizer CEO Albert Bourla discusses leaving Europe to pursue the American dream, highlighting the 'enormous' opportunities in the U.S. He acknowledges American society is not perfect but describes it as an 'oasis in a desert' compared to other societies.